Kytopen is a Cambridge, Massachusetts biotech and MIT spinout building Flowfect, a non-viral, continuous-flow platform that uses fluid flow plus electric fields to deliver mRNA, DNA and CRISPR payloads into cells. The technology aims to engineer hundreds of billions of cells in minutes, removing a major bottleneck in discovering, developing and manufacturing advanced cell therapies like CAR-T and NK-cell treatments.
OPT Industries is an MIT-spun materials foundry in Medford, Massachusetts that built the world's first roll-to-roll 3D printing platform, RAMP. By pairing computational design software with continuous additive manufacturing, OPT prints micron-precise materials at unlimited length and high volume - producing everything from the InstaSwab COVID-19 nasal swab to flockless cosmetic applicators and false eyelashes. The pitch is simple: one process, endless possibilities.
Quaise Energy is an MIT spinout commercializing millimeter wave drilling, a technique that uses powerful gyrotrons to vaporize rock and bore holes up to 20 km deep - far deeper than conventional bits can reach. The goal is to tap superhot geothermal heat (up to ~500 C) almost anywhere on Earth, turning geothermal into a scalable, carbon-free baseload power source that can be delivered through existing power plant infrastructure.
Strand Therapeutics is a clinical-stage biotech building 'programmable' mRNA medicines - drugs engineered with logic circuits so they switch on the right protein, in the right cell, at the right time. Spun out of MIT in 2017 by synthetic biologists who wrote the first programming language for mRNA, Strand's lead candidate STX-001 is a self-replicating mRNA that makes tumors manufacture their own IL-12, turning cold cancers hot from the inside. Backed by Kinnevik, Regeneron, Amgen and Eli Lilly with over $250M raised.